BCR-ABL1 p210 (e13a2/e14a2) defines chronic-phase CML and is the paradigm targeted-therap...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BMA-BCR-ABL1-P210-CML |
|---|---|
| Type | Pertinence thérapeutique |
| État | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Maladies | DIS-CML |
| Sources | SRC-ASCEMBL-REA-2021 SRC-CIVIC SRC-ELN-CML-2025 SRC-IRIS-OBRIEN-2003 |
Faits relatifs à l ' action en justice
| Biomarqueur | BIO-BCR-ABL1 |
|---|---|
| Variante | p210 (e13a2 / e14a2) — typical CML |
| Maladie | DIS-CML |
| Niveau ESCAT | IA |
| Combinaisons recommandées | imatinib monotherapy (1L, low-cost standard), dasatinib monotherapy (1L), nilotinib monotherapy (1L), bosutinib monotherapy (1L), asciminib monotherapy (resistant or 1L per ASC4FIRST) |
| Résumé des faits | BCR-ABL1 p210 (e13a2/e14a2) defines chronic-phase CML and is the paradigm targeted-therapy success story. Imatinib 1L (IRIS, O'Brien 2003) established BCR-ABL1 TKI as standard; 2nd-gen TKIs (dasatinib/nilotinib/bosutinib) achieve faster, deeper molecular responses with similar OS. Asciminib (ASCEMBL, Réa 2021) is the first STAMP-class allosteric TKI for resistant disease. |
Notes
ESCAT IA. OncoKB Level 1. Monitoring by RT-qPCR on International Scale; MMR (≤0.1% IS at 12mo) defines optimal response per ELN 2020/2025. Choice of 1L TKI driven by comorbidity profile (cardiovascular for nilotinib; pleural effusion for dasatinib; etc.).
Utilisé par
No reverse references found in the YAML corpus.